M. J. Ellis, L. Ding, D. Shen, J. Luo, V. J. Suman et al., Whole-genome analysis informs breast cancer response to aromatase inhibition, Nature, vol.486, issue.7403, p.3383766, 2012.

, Comprehensive molecular portraits of human breast tumours, Nature, vol.490, issue.7418, pp.61-70, 2012.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, P. J. Campbell, and M. R. Stratton, Deciphering signatures of mutational processes operative in human cancer, PubMed Central PMCID, vol.3, issue.1, p.3588146, 2013.

M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, issue.10, pp.883-92, 2012.

M. C. Haffner, T. Mosbruger, D. M. Esopi, H. Fedor, C. M. Heaphy et al., Tracking the clonal origin of lethal prostate cancer, J Clin Invest, vol.123, issue.11, 2013.

F. Andre, T. Bachelot, F. Commo, M. Campone, M. Arnedos et al., Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, vol.15, issue.3, p.24508104, 2014.

L. Tourneau, C. Delord, J. P. Gonçalves, A. Gavoille, C. Dubot et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, issue.13, pp.1324-1358, 2015.

A. Gnirke, A. Melnikov, J. Maguire, P. Rogov, E. M. Leproust et al., Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, Nat Biotechnol, vol.27, issue.2, p.19182786, 2009.

H. Li and R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler transform, Bioinformatics, vol.26, issue.5, p.2828108, 2010.

A. Mckenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, vol.20, issue.9, p.20644199, 2010.

K. Cibulskis, M. S. Lawrence, S. L. Carter, A. Sivachenko, D. Jaffe et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, vol.31, issue.3, p.23396013, 2013.

G. Narzisi, J. A. O'rawe, I. Iossifov, H. Fang, Y. H. Lee et al., Accurate de novo and transmitted indel detection in exome-capture data using microassembly, Nat Methods, vol.11, issue.10, p.25128977, 2014.

P. Cingolani, A. Platts, L. Wang-le, M. Coon, T. Nguyen et al., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3, Fly, vol.6, issue.2, p.3679285, 2012.

S. A. Forbes, D. Beare, P. Gunasekaran, K. Leung, N. Bindal et al., COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, vol.43, pp.805-816, 2015.

F. Favero, T. Joshi, A. M. Marquard, N. J. Birkbak, M. Krzystanek et al., Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data, Ann Oncol, vol.26, issue.1, 2015.

S. L. Carter, K. Cibulskis, E. Helman, A. Mckenna, H. Shen et al., Absolute quantification of somatic DNA alterations in human cancer, PubMed Central PMCID, vol.30, issue.5, p.4383288, 2012.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, issue.7457, 2013.

N. D. Dees, Q. Zhang, C. Kandoth, M. C. Wendl, W. Schierding et al., MuSiC: identifying mutational significance in cancer genomes, Genome Res, vol.22, issue.8, p.22759861, 2012.

X. Hua, H. Xu, Y. Yang, J. Zhu, P. Liu et al., DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies, PubMed Central PMCID, vol.93, issue.3, p.3769934, 2013.

C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim et al., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

, Genome Biol, vol.12, issue.4, 2011.

R. Rosenthal, N. Mcgranahan, J. Herrero, B. S. Taylor, and C. Swanton, deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution, Genome Biol, vol.17, issue.1, p.4762164, 2016.

S. Li, D. Shen, J. Shao, R. Crowder, W. Liu et al., Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts, Cell Rep, vol.4, issue.6, p.24055055, 2013.

W. Toy, Y. Shen, H. Won, B. Green, R. A. Sakr et al., ESR1 ligand-binding domain mutations in hormone-resistant breast cancer, Nat Genet, vol.45, issue.12, 2013.

D. R. Robinson, Y. M. Wu, P. Vats, F. Su, R. J. Lonigro et al., Activating ESR1 mutations in hormoneresistant metastatic breast cancer, Nat Genet, vol.45, issue.12, 2013.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, S. A. Aparicio, S. Behjati et al., Signatures of mutational processes in human cancer, Nature, vol.500, issue.7463, pp.415-436, 2013.

N. Mcgranahan, F. Favero, E. C. De-bruin, N. J. Birkbak, Z. Szallasi et al., Clonal status of actionable driver events and the timing of mutational processes in cancer evolution, Sci Transl Med, vol.7, issue.283, 2015.

B. Orsetti, J. Selves, C. Bascoul-mollevi, L. Lasorsa, K. Gordien et al., Impact of chromosomal instability on colorectal cancer progression and outcome, BMC Cancer, vol.14, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00952435

R. Jeselsohn, G. Buchwalter, D. Angelis, C. Brown, M. Schiff et al., ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer, Nat Rev Clin Oncol, vol.12, issue.10, pp.573-83, 2015.

N. C. Turner, H. Bartlett, C. Cristofanilli, and M. , Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, vol.373, issue.17, pp.1672-1675, 2015.

C. Cybulski, W. Kluzniak, T. Huzarski, D. Wokolorczyk, A. Kashyap et al., Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis, Lancet Oncol, vol.16, issue.6, p.25959805, 2015.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al., Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, vol.366, issue.6, p.22149876, 2012.

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke et al., Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer, N Engl J Med, vol.375, issue.18, pp.1738-1786, 2016.

D. J. Lobbezoo, R. J. Van-kampen, A. C. Voogd, M. W. Dercksen, F. Van-den-berkmortel et al., In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium, Ann Oncol, vol.27, issue.2, pp.256-62, 2016.